Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-036 ...

Exhibit 99.1 Ekso Bionics Announces Third Quarter 2024 Financial Results SAN RAFAEL, Calif., October 28, 2024 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2024. Recent Highlights and Accomplishments ● Reported revenue of $4.1 million in the third quarter of 2024 ● Sold a total of 33 EksoHealth devices in the third quarter of 2024 ● ...

SAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2024. Recent Highlights and Accomplishments Reported revenue of $4.1 million in the third quarter of 2024 Sold a total of 33 EksoHealth devices in the third quarter of 2024 Announced receipt of initial Centers for Medicare & Medicaid Serv ...

SAN RAFAEL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2024 after the close of trading on Monday, October 28, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcast of the e ...

SAN RAFAEL, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today announced the pricing of an underwritten public offering of 6,000,000 total units and pre-funded units for gross proceeds of approximately $6.0 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 3,100,000 units, priced at a public ...

Ekso Bionics (EKSO) has reached a significant milestone in terms of transforming mobility solutions, particularly for individuals with spinal cord injuries (SCI). The company recently secured initial reimbursement from the Centers for Medicare & Medicaid Services (CMS) for its Ekso Indego Personal exoskeleton. This achievement is poised to expand Ekso Bionics' foothold in the growing exoskeleton technology market, which is gaining traction in both medical and industrial sectors. Strategic Implications The C ...

Ekso Bionics CEO Scott Davis said the following in the Q2 earnings report. The bad news for Ekso Bionics starts with its diluted earnings per share of -13 cents. That's worse than the -11 cents per share Wall Street was expecting. Even if it's an improvement over the company's -31 cents per share from the same period of the year prior. "With the Medicare reimbursement mechanisms in place, we are focused on reaching a larger U.S. population of individuals living with a spinal cord injury ("SCI") and anticipa ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Scott Davis - Chief Executive Officer Jerome Wong - Chief Financial Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Li Chen - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics' Q2 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will foll ...

Another stock from the same industry, Accelerate Diagnostics (AXDX) , has yet to report results for the quarter ended June 2024. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Ekso Bionics (EKSO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. Ekso Bionics, which belongs to the Zacks Medical - Instruments ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or Table of Contents FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 ...